NEUREN PHARMACEUTICALS LIMITED - Announcements

5.76%

$13.10

Market Cap $1.629B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

MEMPHASYS LIMITED

Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive biotechnology. Driven by market needs, Memphasys is developing a portfolio of device, diagnostic and media products that address human and animal reproduction issues.

Announcements

Filter Results

All Price Sensitive Only

NEU	NNZ-2591 positive effects in Phelan-McDermid syndrome model	PRICE SENSITIVE	18/02/19	109KB	Share
NEU	Plans for Phase 3 trial in Rett syndrome		04/02/19	72.55KB	Share
NEU	Neuren retains ex-North America, appoints investment bank		01/02/19	104.67KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	47.82KB	Share
NEU	Final Director's Interest Notice		03/01/19	61.4KB	Share
NEU	Ceasing to be a substantial holder		31/12/18	109.75KB	Share
NEU	2018 Year-end Business Update		18/12/18	125.82KB	Share
NEU	Larry Glass to retire as a director and continue as CSO		17/12/18	101.89KB	Share
NEU	Presentation at AusBiotech Invest and Partnering 2018		02/11/18	297.32KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18	75.3KB	Share
NEU	Trofinetide ex-North America exclusive negotiation period	PRICE SENSITIVE	26/10/18	100.3KB	Share
NEU	Neuren and ACADIA hold Rett syndrome SAB meeting		17/10/18	102.36KB	Share
NEU	Change of Director's Interest Notice		01/10/18	34.41KB	Share
NEU	FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID		21/09/18	231.09KB	Share
NEU	Investor presentation, 6 September 2018		06/09/18	899.74KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	31/08/18	713.9KB	Share
NEU	Neuren and Lanstead agree to pause settlements for 120 days	PRICE SENSITIVE	29/08/18	102.56KB	Share
NEU	Appointment of auditor		22/08/18	54.1KB	Share
NEU	Neuren receives initial payment of US$10 million from ACADIA	PRICE SENSITIVE	22/08/18	119.21KB	Share
NEU	Change of Director's Interest Notice		16/08/18	34.38KB	Share
NEU	Change of Director's Interest Notice		15/08/18	34.49KB	Share
NEU	Investor update		07/08/18	83.01KB	Share
NEU	Neuren and ACADIA announce agreement for North America	PRICE SENSITIVE	07/08/18	222.12KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18	47.69KB	Share
NEU	Initial Director's Interest Notice		09/07/18	62.92KB	Share
NEU	Initial Director's Interest Notice		05/07/18	63.03KB	Share
NEU	Initial Director's Interest Notice		05/07/18	62.82KB	Share
NEU	Neuren announces new appointments to the board of directors		04/07/18	103.77KB	Share
NEU	Results of Meeting		18/06/18	57.13KB	Share
NEU	Chairman's Address at 2018 Annual Shareholders' Meeting		18/06/18	119.92KB	Share
NEU	Change of Director's Interest Notice		30/05/18	41.04KB	Share
NEU	Final share buy-back notice - Appendix 3F		30/05/18	63.11KB	Share
NEU	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	30/05/18	74.27KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		23/05/18	26.99KB	Share
NEU	Appendix 3B		23/05/18	104.19KB	Share
NEU	Neuren announces investment and exclusive negotiation period	PRICE SENSITIVE	21/05/18	99.49KB	Share
NEU	Notice of Annual General Meeting/Proxy Form		14/05/18	194.51KB	Share
NEU	Appendix 4G		08/05/18	124.04KB	Share
NEU	Annual Report to shareholders		08/05/18	3.32MB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	62.65KB	Share
NEU	First patent in Japan granted for Neuren's trofinetide	PRICE SENSITIVE	30/04/18	99.59KB	Share
NEU	Full Year Statutory Accounts		29/03/18	12.4MB	Share
NEU	Disclosure under Listing Rule 4.3D	PRICE SENSITIVE	29/03/18	132.17KB	Share
NEU	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	09/03/18	201.26KB	Share
NEU	Preliminary Final Report	PRICE SENSITIVE	28/02/18	65.52KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/18	47.77KB	Share
NEU	Final Director's Interest Notice		29/12/17	61.3KB	Share
NEU	Non-executive director retirement		29/12/17	98.9KB	Share
NEU	Change in substantial holding		27/12/17	158.68KB	Share
NEU	Neuren announces new US patent to be granted for NNZ-2591	PRICE SENSITIVE	05/12/17	103.84KB	Share
NEU	Consolidation/Split - NEU	PRICE SENSITIVE	16/11/17	25.08KB	Share
NEU	Notification under Listing Rule 7.20 of share reorganisation		16/11/17	82.9KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	26/10/17	48.91KB	Share
NEU	Neuren FDA meeting confirms Phase 3 plan for Rett syndrome	PRICE SENSITIVE	13/10/17	102.03KB	Share
NEU	Investor presentation, 6 October 2017		06/10/17	888.37KB	Share
NEU	Presentations and publication for Rett syndrome trials	PRICE SENSITIVE	05/10/17	108.16KB	Share
NEU	Change of Director's Interest Notice		30/08/17	40.24KB	Share
NEU	Change of Director's Interest Notice		30/08/17	34.36KB	Share
NEU	Change of Director's Interest Notice		30/08/17	34.67KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		29/08/17	27.05KB	Share
NEU	Appendix 3B		29/08/17	104.61KB	Share
NEU	Results of Meeting		29/08/17	63.39KB	Share
NEU	Neuren reports 2017 half-year results		24/08/17	129.81KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	24/08/17	1.29MB	Share
NEU	Notice of special meeting of shareholders		14/08/17	183.58KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/17	74.29KB	Share
NEU	Becoming a substantial holder		21/07/17	151.09KB	Share
NEU	Neuren granted Type B Meeting with FDA for Rett syndrome	PRICE SENSITIVE	20/07/17	100.95KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		19/07/17	26.92KB	Share
NEU	Appendix 3B		19/07/17	104.6KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		13/07/17	27.08KB	Share
NEU	Appendix 3B		13/07/17	104.53KB	Share
NEU	Results of Meeting		29/06/17	59.04KB	Share
NEU	2017 AGM Chairman's Address		29/06/17	126.18KB	Share
NEU	Neuren secures funding for key activities for Rett syndrome	PRICE SENSITIVE	29/06/17	121.62KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	28/06/17	429.31KB	Share
NEU	Trading Halt	PRICE SENSITIVE	27/06/17	307.79KB	Share
NEU	Investor presentation, 2 June 2017		02/06/17	649.39KB	Share
NEU	Neuren announces grant of two new patents to 2032	PRICE SENSITIVE	31/05/17	103.2KB	Share
NEU	Notice of Annual General Meeting/Proxy Form		29/05/17	383.76KB	Share
NEU	Response to Appendix 4C Query	PRICE SENSITIVE	08/05/17	434.08KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/17	71.59KB	Share
NEU	Appendix 4G		28/04/17	122.45KB	Share
NEU	Annual Report to shareholders		28/04/17	6.82MB	Share
NEU	Neuren receives $1 million R&D Tax Incentive	PRICE SENSITIVE	04/04/17	97.8KB	Share
NEU	Investor presentation, 3 April 2017		03/04/17	659.05KB	Share
NEU	Full Year Statutory Accounts		30/03/17	10.03MB	Share
NEU	Trofinetide significant clinical benefit in Rett syndrome	PRICE SENSITIVE	22/03/17	727.42KB	Share
NEU	Trading Halt	PRICE SENSITIVE	17/03/17	306.42KB	Share
NEU	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	10/03/17	177.37KB	Share
NEU	Preliminary Final Report	PRICE SENSITIVE	23/02/17	90.75KB	Share
NEU	Investor presentation, 2 February 2017		02/02/17	497.55KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/17	71.9KB	Share
NEU	Neuren completes Phase 2 trial in pediatric Rett syndrome	PRICE SENSITIVE	30/01/17	115.21KB	Share
NEU	Results of Meeting		06/12/16	72.8KB	Share
NEU	Investor presentation, 25 November 2016		25/11/16	496.99KB	Share
NEU	Notice of special meeting of shareholders	PRICE SENSITIVE	14/11/16	523.49KB	Share
NEU	Neuren completes enrolment in Rett syndrome Phase 2 trial	PRICE SENSITIVE	14/11/16	116.39KB	Share
NEU	Appendix 4C - quarterly-NEU.AX	PRICE SENSITIVE	31/10/16	74.31KB	Share
NEU	Neuren receives $0.9m from exercise of last expiring options-NEU.AX	PRICE SENSITIVE	28/10/16	102.44KB	Share

NEU NNZ-2591 positive effects in Phelan-McDermid syndrome model
18/02/19	PRICE SENSITIVE	109KB	Share
NEU Plans for Phase 3 trial in Rett syndrome
04/02/19		72.55KB	Share
NEU Neuren retains ex-North America, appoints investment bank
01/02/19		104.67KB	Share
NEU Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	47.82KB	Share
NEU Final Director's Interest Notice
03/01/19		61.4KB	Share
NEU Ceasing to be a substantial holder
31/12/18		109.75KB	Share
NEU 2018 Year-end Business Update
18/12/18		125.82KB	Share
NEU Larry Glass to retire as a director and continue as CSO
17/12/18		101.89KB	Share
NEU Presentation at AusBiotech Invest and Partnering 2018
02/11/18		297.32KB	Share
NEU Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE	75.3KB	Share
NEU Trofinetide ex-North America exclusive negotiation period
26/10/18	PRICE SENSITIVE	100.3KB	Share
NEU Neuren and ACADIA hold Rett syndrome SAB meeting
17/10/18		102.36KB	Share
NEU Change of Director's Interest Notice
01/10/18		34.41KB	Share
NEU FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID
21/09/18		231.09KB	Share
NEU Investor presentation, 6 September 2018
06/09/18		899.74KB	Share
NEU Half Yearly Report and Accounts
31/08/18	PRICE SENSITIVE	713.9KB	Share
NEU Neuren and Lanstead agree to pause settlements for 120 days
29/08/18	PRICE SENSITIVE	102.56KB	Share
NEU Appointment of auditor
22/08/18		54.1KB	Share
NEU Neuren receives initial payment of US$10 million from ACADIA
22/08/18	PRICE SENSITIVE	119.21KB	Share
NEU Change of Director's Interest Notice
16/08/18		34.38KB	Share
NEU Change of Director's Interest Notice
15/08/18		34.49KB	Share
NEU Investor update
07/08/18		83.01KB	Share
NEU Neuren and ACADIA announce agreement for North America
07/08/18	PRICE SENSITIVE	222.12KB	Share
NEU Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE	47.69KB	Share
NEU Initial Director's Interest Notice
09/07/18		62.92KB	Share
NEU Initial Director's Interest Notice
05/07/18		63.03KB	Share
NEU Initial Director's Interest Notice
05/07/18		62.82KB	Share
NEU Neuren announces new appointments to the board of directors
04/07/18		103.77KB	Share
NEU Results of Meeting
18/06/18		57.13KB	Share
NEU Chairman's Address at 2018 Annual Shareholders' Meeting
18/06/18		119.92KB	Share
NEU Change of Director's Interest Notice
30/05/18		41.04KB	Share
NEU Final share buy-back notice - Appendix 3F
30/05/18		63.11KB	Share
NEU Announcement of buy-back - Appendix 3C
30/05/18	PRICE SENSITIVE	74.27KB	Share
NEU Notice under section 708A(5)(e) of the Corporations Act
23/05/18		26.99KB	Share
NEU Appendix 3B
23/05/18		104.19KB	Share
NEU Neuren announces investment and exclusive negotiation period
21/05/18	PRICE SENSITIVE	99.49KB	Share
NEU Notice of Annual General Meeting/Proxy Form
14/05/18		194.51KB	Share
NEU Appendix 4G
08/05/18		124.04KB	Share
NEU Annual Report to shareholders
08/05/18		3.32MB	Share
NEU Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	62.65KB	Share
NEU First patent in Japan granted for Neuren's trofinetide
30/04/18	PRICE SENSITIVE	99.59KB	Share
NEU Full Year Statutory Accounts
29/03/18		12.4MB	Share
NEU Disclosure under Listing Rule 4.3D
29/03/18	PRICE SENSITIVE	132.17KB	Share
NEU S&P DJ Indices Announces March Quarterly Rebalance
09/03/18	PRICE SENSITIVE	201.26KB	Share
NEU Preliminary Final Report
28/02/18	PRICE SENSITIVE	65.52KB	Share
NEU Appendix 4C - quarterly
30/01/18	PRICE SENSITIVE	47.77KB	Share
NEU Final Director's Interest Notice
29/12/17		61.3KB	Share
NEU Non-executive director retirement
29/12/17		98.9KB	Share
NEU Change in substantial holding
27/12/17		158.68KB	Share
NEU Neuren announces new US patent to be granted for NNZ-2591
05/12/17	PRICE SENSITIVE	103.84KB	Share
NEU Consolidation/Split - NEU
16/11/17	PRICE SENSITIVE	25.08KB	Share
NEU Notification under Listing Rule 7.20 of share reorganisation
16/11/17		82.9KB	Share
NEU Appendix 4C - quarterly
26/10/17	PRICE SENSITIVE	48.91KB	Share
NEU Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
13/10/17	PRICE SENSITIVE	102.03KB	Share
NEU Investor presentation, 6 October 2017
06/10/17		888.37KB	Share
NEU Presentations and publication for Rett syndrome trials
05/10/17	PRICE SENSITIVE	108.16KB	Share
NEU Change of Director's Interest Notice
30/08/17		40.24KB	Share
NEU Change of Director's Interest Notice
30/08/17		34.36KB	Share
NEU Change of Director's Interest Notice
30/08/17		34.67KB	Share
NEU Notice under section 708A(5)(e) of the Corporations Act
29/08/17		27.05KB	Share
NEU Appendix 3B
29/08/17		104.61KB	Share
NEU Results of Meeting
29/08/17		63.39KB	Share
NEU Neuren reports 2017 half-year results
24/08/17		129.81KB	Share
NEU Half Yearly Report and Accounts
24/08/17	PRICE SENSITIVE	1.29MB	Share
NEU Notice of special meeting of shareholders
14/08/17		183.58KB	Share
NEU Appendix 4C - quarterly
27/07/17	PRICE SENSITIVE	74.29KB	Share
NEU Becoming a substantial holder
21/07/17		151.09KB	Share
NEU Neuren granted Type B Meeting with FDA for Rett syndrome
20/07/17	PRICE SENSITIVE	100.95KB	Share
NEU Notice under section 708A(5)(e) of the Corporations Act
19/07/17		26.92KB	Share
NEU Appendix 3B
19/07/17		104.6KB	Share
NEU Notice under section 708A(5)(e) of the Corporations Act
13/07/17		27.08KB	Share
NEU Appendix 3B
13/07/17		104.53KB	Share
NEU Results of Meeting
29/06/17		59.04KB	Share
NEU 2017 AGM Chairman's Address
29/06/17		126.18KB	Share
NEU Neuren secures funding for key activities for Rett syndrome
29/06/17	PRICE SENSITIVE	121.62KB	Share
NEU Response to ASX Price Query
28/06/17	PRICE SENSITIVE	429.31KB	Share
NEU Trading Halt
27/06/17	PRICE SENSITIVE	307.79KB	Share
NEU Investor presentation, 2 June 2017
02/06/17		649.39KB	Share
NEU Neuren announces grant of two new patents to 2032
31/05/17	PRICE SENSITIVE	103.2KB	Share
NEU Notice of Annual General Meeting/Proxy Form
29/05/17		383.76KB	Share
NEU Response to Appendix 4C Query
08/05/17	PRICE SENSITIVE	434.08KB	Share
NEU Appendix 4C - quarterly
28/04/17	PRICE SENSITIVE	71.59KB	Share
NEU Appendix 4G
28/04/17		122.45KB	Share
NEU Annual Report to shareholders
28/04/17		6.82MB	Share
NEU Neuren receives $1 million R&D Tax Incentive
04/04/17	PRICE SENSITIVE	97.8KB	Share
NEU Investor presentation, 3 April 2017
03/04/17		659.05KB	Share
NEU Full Year Statutory Accounts
30/03/17		10.03MB	Share
NEU Trofinetide significant clinical benefit in Rett syndrome
22/03/17	PRICE SENSITIVE	727.42KB	Share
NEU Trading Halt
17/03/17	PRICE SENSITIVE	306.42KB	Share
NEU S&P DJ Indices Announces March Quarterly Rebalance
10/03/17	PRICE SENSITIVE	177.37KB	Share
NEU Preliminary Final Report
23/02/17	PRICE SENSITIVE	90.75KB	Share
NEU Investor presentation, 2 February 2017
02/02/17		497.55KB	Share
NEU Appendix 4C - quarterly
31/01/17	PRICE SENSITIVE	71.9KB	Share
NEU Neuren completes Phase 2 trial in pediatric Rett syndrome
30/01/17	PRICE SENSITIVE	115.21KB	Share
NEU Results of Meeting
06/12/16		72.8KB	Share
NEU Investor presentation, 25 November 2016
25/11/16		496.99KB	Share
NEU Notice of special meeting of shareholders
14/11/16	PRICE SENSITIVE	523.49KB	Share
NEU Neuren completes enrolment in Rett syndrome Phase 2 trial
14/11/16	PRICE SENSITIVE	116.39KB	Share
NEU Appendix 4C - quarterly-NEU.AX
31/10/16	PRICE SENSITIVE	74.31KB	Share
NEU Neuren receives $0.9m from exercise of last expiring options-NEU.AX
28/10/16	PRICE SENSITIVE	102.44KB	Share

REFRESH

First 3 4 5 6 7

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.10		Change -0.800(5.76%)		Mkt cap ! $1.629B

Open	High	Low	Value	Volume
$13.95	$13.96	$12.88	$9.534M	725.6K

Buyers (Bids)

No.	Vol.	Price($)
1	266	$13.10

Sellers (Offers)

Price($)	Vol.	No.
$13.15	1619	2

View Market Depth

No.	Vol.	Price($)
1	667	13.080
2	154	13.000
1	77	12.930
1	39	12.920
1	21	12.900

Price($)	Vol.	No.
13.190	1305	1
13.560	2250	1
13.880	748	1
14.000	60	1
14.020	10000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories